Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011 Abstract - Primary - Primary - GI - N0147
Analysis of time-dependent patterns of treatment effect and failure to explain the predictive role of deficient mismatch repair (dMMR) in stage II and III colon cancer (CC) Kim, G. P. , Marsoni, S. , Monges, G. , Allegra, C. J. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - GI - N994C
Time-dependent patterns of treatment effect and failure as an explanation for the predictive role of deficient mismatch repair (dMMR) in colon cancer. Kim, G. , Marsoni, S. , Monges, G. , Allegra, C. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary - Primary - GI - NCCTG-N994C
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
EGFR expression is associated with increased cell turnover and poor histologic grade in human colon carcinomas. Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0442
Activated EGFR as a prognostic marker in human colon cancer Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Primary - GI - N0442
Mutations in the proapoptotic BAX gene are associated with defective DNA mismatch repair and altered tumor growth rates in human colon cancers Sinicrope, F. A. , Rego, R. L. , French, A. J. , Foster, N. R. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0442
Evaluation of recurrence rate,time-to-recurrence, and hepatic metastases in patients with colon cancers with defective DNA mismatch repair. Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Thibodeau, S. N. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2010 Abstract - Secondary - Primary - GI - NCCTG-N994C
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance) Yoon, H. H. , Tougeron, D. , Mahoney, M. R. , Shi, Q. , Sargent, D. J. ... - - European Journal of Cancer - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
